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We used results from a national tuberculosis prevalence 
survey in Eritrea to calculate case detection rate (CDR) and 
compared it with the published CDR. The CDR obtained 
from the survey was ≈40%, whereas the CDR published by 
the World Health Organization was 3× lower (14%). 
During the World Health Assembly in 1991, 2 targets were set for tuberculosis (TB) control: to detect 70% 
of all new sputum smear–positive cases arising each year 
and to successfully treat 85% of these cases (1). For as-
sessment of the fi rst target, case detection rate (CDR) is 
used; CDR is the number of cases reported divided by the 
number of incident cases estimated for that year. In Africa 
in 2004, the range of CDRs for new smear-positive TB pa-
tients was 14%–115% in different countries (2). The CDR 
is uncertain for many African countries because informa-
tion for estimating the incidence is outdated or unavailable. 
The most recent national TB prevalence surveys were per-
formed from 1955 through 1960; they covered 11 countries 
and a population of ≈40,000 (3). Since then, TB treatment 
has become widely available, and the emergence of HIV 
has had a substantial effect on TB incidence (4,5).
Recently, a TB prevalence survey was performed in 
Eritrea, a country with a population of 3 million, located in 
the Horn of Africa (6). The survey determined the preva-
lence of sputum smear–positive TB by examining sputum 
samples of persons >15 years of age. To assess the perfor-
mance of Eritrea’s TB program, we calculated the CDR by 
using information obtained from the survey and compared 
this CDR to published estimates.
The Study
The national TB prevalence survey in Eritrea was con-
ducted from February through October 2005 (6). In 40 se-
lected villages, a census (which included information about 
sex and age) was taken of ≈875 persons in each village. All 
persons >15 years of age were asked to provide a morning 
and a spot sputum sample. Persons were informed about 
the survey and could refuse participation. The study proto-
col for the prevalence survey was approved by the Ministry 
of Health. 
The specimens were examined by fl uorescence mi-
croscopy. Samples positive by fl uorescence microscopy 
were reexamined by light microscopy for confi rmation. 
Persons who had 2 positive sputum samples were in-
formed about the test results and referred for treatment. 
Those who had 1 positive sputum sample were referred 
to a nearby healthcare facility for further smear exami-
nation. If results of smear examination were negative, 
thoracic radiographs were taken and evaluated by 2 ex-
perienced radiologists. The case defi nition for a sputum 
smear–positive case was at least 2 sputum specimens 
positive for acid-fast bacilli by Ziehl-Neelsen staining 
and microscopy or at least 1 sputum specimen positive for 
acid-fast bacilli and radiographic abnormalities consistent 
with active pulmonary TB (classifi cation of the National 
Tuberculosis Control Program in Eritrea).
Using the prevalence estimate obtained from the sur-
vey and 2 different models, we calculated the CDR for 
2004. In model 1, described by Styblo, CDR = (notifi cation 
rate/prevalence rate) / (0.5 + 0.83 × [notifi cation rate/preva-
lence rate]) (7,8). In model 2, described by Dye et al., CDR 
= (notifi cation rate/prevalence rate) / ([notifi cation rate/
prevalence rate] + 0.5) (9,10). We then compared the cal-
culated CDR with the CDR estimated by the World Health 
Organization (WHO) to evaluate whether comparable con-
clusions about TB case detection would be obtained.
A total of 38,047 persons were included in the preva-
lence survey. Of those >15 years of age, 18,152 (94.6%) 
provided at least 1 sputum sample (Figure). The prevalence 
of new smear-positive TB was estimated at 90/100,000 
(95% confi dence interval [CI] 35–145/100,000) in persons 
>15 years of age. In 2005, 44.7% of the Eritrean popula-
tion was <15 years of age (11), which resulted in an overall 
new smear-positive TB prevalence of 50/100,000 (95% CI 
19–80/100,000) under the assumption of no cases in per-
sons <15 years of age.
In 2004, 17/100,000 new smear-positive cases were 
reported (2). The calculated CDR from model 1 was 43% 
and from model 2 was 40%. The 2004 CDR published by 
WHO was 14%.
Conclusions
For Eritrea, the CDR provided by WHO is consider-
ably lower than that calculated from the results of the na-
tional TB prevalence survey. Both estimates indicate that 
Eritrea has not reached the 70% target for case detection. 
However, the WHO estimate suggests that the program 
needs to improve case detection by a factor of 5, whereas 
the survey estimate suggests that case detection needs to be 
improved by a factor of 1.6. Two explanations may account 
for the large difference: 1) the CDR derived from the TB 
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prevalence survey is too high because of an underestima-
tion of the prevalence of smear-positive TB, or 2) the CDR 
estimate published by WHO is too low because of an over-
estimation of the incidence of smear-positive TB.
In the national TB prevalence survey, measures were 
taken to ensure high quality of the results; e.g., training of 
data collectors, repeat census taking, reexamination of all 
slides found positive on fl uorescence microscopy, and re-
examination of a 5% random sample of the negative slides. 
Persons who had smear-positive TB may have been missed 
because they did not provide a specimen; however, because 
only 5% of eligible persons did not provide a specimen, this 
can explain only a slight underestimation. Furthermore, re-
corded reasons for not providing a specimen seem to be 
unrelated to a higher chance of having TB. The quality of 
the provided specimens may have been suboptimal because 
instructing and motivating persons to provide a sputum 
sample is challenging. For diagnosis of TB, microscopic 
examination of saliva is less sensitive than examination of 
sputum; however, in ≈50% of saliva samples from patients 
with a positive sputum sample, bacilli can be demonstrated 
(12,13). For 27,647 samples that appeared to be saliva, 
smear–positive results were obtained for 12. Assuming that 
only 50% were detected, a maximum of 12 smear-positive 
TB patients may have been undetected. Taking this into 
account results in a prevalence of 87/100,000. Using this 
estimate, model 1 provides a CDR of 30% and model 2 
a CDR of 28%; both fi gures are still substantially higher 
than the WHO CDR of 14%. The possibility that persons 
who provided a saliva sample were not able to produce a 
sputum sample because they did not have pathologic pul-
monary changes should also be taken into consideration. If 
so, the estimated prevalence is correct.
Estimation of the incidence of smear-positive TB in 
Eritrea is complicated by the fact that no data from tuber-
culin or prevalence surveys were available. The only data 
available for Eritrea were reporting data, which experts 
assessed as being of low quality (14). Use of this limited 
information will result in an uncertain incidence estimate, 
which may result in an unreliable CDR.
For most countries in Africa, little information is avail-
able for estimating the prevalence of disease and prog-
ress towards the Millennium Development Goals (http://
unstats.un.org/unsd/mi/mi_goals.asp, accessed 2006 Aug 
30). On the basis of case reporting, TB was rightly declared 
an emergency by African health ministers at the WHO Af-
rica Regional Committee in Maputo in 2005 (15). To be 
able to fi ght this emergency, more reliable information 
about the prevalence of TB in Africa is needed. Further-
more, for global TB control, reliable information about the 
TB epidemic in Africa is needed because 28% of the in-
cident smear-positive cases occurred in the WHO African 
region in 2004 (2).
In conclusion, the example of Eritrea shows that a 
large gap may exist between available estimates of TB 
prevalence and actual TB prevalence in Africa. National 
TB prevalence surveys in Africa would help provide better 
information on TB prevalence and case detection.
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